<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895750</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0008</org_study_id>
    <nct_id>NCT02895750</nct_id>
  </id_info>
  <brief_title>Efficacity and Safety of Metformin XR in CKD Stage 1 to 3</brief_title>
  <acronym>METXR/CKD</acronym>
  <official_title>Efficacity and Safety of Metformin XR in CKD Stage 1 to 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and
      there is no available data in chronic kidney disease (CKD). The planned study aims to provide
      data on glucose plasma level in relation to metformin plasma level in Diabetes Type II
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of once daily Metformin XR on 24-h blood glucose control</measure>
    <time_frame>week 12</time_frame>
    <description>The blood glucose will be measured continuously throughout the study using continuous glucose monitoring (mean, range and variability in each therapeutic block).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Metformin XR in mild to moderate (CKD)</measure>
    <time_frame>week 0, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Blood creatinine levels will be measured at the end of each therapeutic block. (week 0, 2, 4, 6, 8, 10 and 12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Metformin XR in mild to moderate (CKD) 2</measure>
    <time_frame>week 0, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>blood lactate levels will be measured at the end of each therapeutic block.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>normal to mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 subjects): eGFR â‰¥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild to moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate to severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>normal to mild renal impairment</arm_group_label>
    <arm_group_label>mild to moderate renal impairment</arm_group_label>
    <arm_group_label>moderate to severe renal impairment</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any
             other antidiabetic treatment)

        Exclusion Criteria:

          -  Pregnancy and lactation

          -  Hyperlactatemia (&gt; 2.5 mmol/L)

          -  No creatinine levels available since 3 months

          -  Severe hepatic insufficiency

          -  No liver function parameters available

          -  Need of investigation with iodized contrast media

          -  Hypersensitivity to metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
    <phone>+33 3 22 45 58 95</phone>
    <email>lalau.jean-daniel@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Daniel LALAU, MD, PhD</last_name>
      <phone>+33 3 22 45 58 95</phone>
      <email>lalau.jean-daniel@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes type 2</keyword>
  <keyword>Metformin</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

